Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
Infections caused by carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β-lactamase inhibitor combination, ha...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/12/12/1729 |